Bienaime Jean Jacques

DirectorKeros Therapeutics, Inc. (KROS) · full profile →Form 4 · filed Aug 19, 2026
Net Buying
Open-Market Buys
$10K
Open-Market Sells
$0
Net Open-Market Flow
$10K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 17, 2026Buy(P)1K$10.27$10K20K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001221590-26-000025) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.